laboratori corp america hold
laboratori corp america hold || north
ceo adam schecter debut call unveil strateg vision
labcorp revamp cro focu combin strong
execut path earn acceler
reiter ow rate rais pt
laboratori corp america
strategi focus strengthen integr drug develop diagnost
platform discuss call underscor opportun covanc
strengthen drug develop platform leverag diagnost capabl
deepen relationship big pharma client broaden scope trial
oncolog highlight primari near-term opportun follow
diagnost price surprisingli strong quarter
normal pama beacon lb headwind strongest
benefit guidanc suggest price level
focu tuck small region lab accret within first
year return cost capit within year labcorp deploy
million exclud cash paid envigo acquisit fund tuck-in
acquisit diagnost decemb quarter
said consist commentari quest call deal take longer
anticip close
contribut prefer lab network pln
embed outlook contrast quest expect see volum
uplift pln labcorp approach measur suggest
opportun longer term natur repres upsid physician adopt
pick
path margin expans launchpad cost save benefit
margin decemb quarter diagnost margin
bp versu averag bp first three quarter manag
increasingli confid close gap save continu ramp
reach million run rate goal offset pama headwind
laboratori corp america hold lh lh us
 distribut unit state america
unless otherwis note metric base modelwar
base consensu methodolog
consensu data provid thomson reuter estim
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
labcorp quest side side comparison pln cost cutting/margin
volum pama pleas see exhibit exhibit
risk reward laboratori corp america hold lh
lt share gain opp pref payor partnership cro faster growth
price-to-earnings base case ep multipl reect discount current
multipl lh averag year discount
thomson reuter morgan stanley research morgan stanley institut equiti divis probabl
bull base bear case scenario play estim impli volatil data option market
feb gure approxim risk-neutr probabl stock reach beyond scenario price
either three-month one-year time view explan option probabl methodolog
labcorp second largest refer
lab compani matur industri
plan open lab
contract establish long-term strateg
partnership labcorp quest
diagnost set stage ration
price share gain opportun
posit lab rel safe haven
within hc servic sector
headwind
reimburs pressur exposur
quanti factor ms/market
cro diversi labcorp busi
view descript risk reward theme
price-to-earnings bull case ep
bull case multipl reect premium
bull case multipl reect premium
current multipl
current multipl
price-to-earnings base case ep
base case multipl reect discount
base case multipl reect discount
current multipl
current multipl
price-to-earnings bear case ep
bear case multipl reect discount
bear case multipl reect discount
current multipl
current multipl
 risk reward laboratori corp america hold lh
laboratori corpor america hold
laboratori corpor america hold
volum growth less scale region
player prefer lab network
china india
view explan region hierarchi
research highest favor quintil
higher core volum growth faster
expect share gain region
revers pama cut
medicar reimburs pressur
abat revers
covanc chiltern deal synergi
fund exposur held mspb inform may
inconsist may reect broader market
exposur sector total net exposur
across sector long exposur short exposur
exhibit comparison pln commentari lh
exhibit comparison cut initi organ volum growth pama
commentari lh
